![]() ![]() Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates. In particular, the platform identifies T cell receptor-antigen pairs in the context of other important features of the immune synapse, such as T cell function and how these antigens are presented by molecules on antigen-presenting cells, known as major human leukocyte antigen, or HLA, molecules. The DECODE platform is a powerful discovery engine that characterizes essential elements of the immune synapse. "By identifying the relevant TCR-antigen pairs, we may be able to improve the specificity of patient treatment, which could lead to improved outcomes." "Through this collaboration with Repertoire, we hope to identify the TCR-antigen pairs that successfully protect from tumor formation in patients at various stages of their cancer," said Nadeem Riaz, MD, MSc., Director for Precision Radiotherapy at MSK. This map of the immune system’s response could inform treatment considerations for patients with inadequately treated disease. By identifying cancer-specific epitopes and the T cells that recognize these epitopes in successfully treated patients, it may be possible to define the optimal immunogenic profile for a proposed treatment. Repertoire’s research collaboration with MSK will also seek to identify the TCR repertoire that is engaged and results in successful treatment outcomes with anti-PD-1 treatment and with conventional chemotherapy-radiation treatment. This discovery may lead to new cell therapies and give us insight into why some patients respond successfully to currently available treatments, while others have poor or no response to treatment." "The goal of this research collaboration between Memorial Sloan Kettering and Repertoire is to identify the TCR-antigen pairs that are activated when the immune system is successful in fighting HPV+ cancers. When cancer spreads, it is a signal that the immune system can no longer recognize or defend against the cancer," said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines. "Understanding the adaptive immune system’s response to cancer allows us to see how it initially responds to diseased cells. Using Repertoire’s DECODE™ platform to map the adaptive immune system’s response can inform the development of novel cell-based therapeutics by confirming the relevant targets for cell-based treatments. The research collaboration aims to identify the antigens present on tumors as well as the T cells and specific T cell receptors (TCRs) that recognize tumor-specific antigens. Identification of T cell receptors, epitopes and antigens involved in each stage of disease progression and during treatment can inform the development of novel therapeutics and improve selection of patient treatmentĬAMBRIDGE, Mass., July 14, 2022-( BUSINESS WIRE)- Repertoire Immune Medicines today announced its research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to identify the immune system’s response at various stages of human papillomavirus-positive (HPV+) cancer, including initial oncogenesis and after successful treatment. Repertoire’s DECODE™ technology will be used to identify the specific T cell receptor (TCR) repertoire in early-stage cancers treated with chemotherapy-radiation and mid- to late-stage cancers treated with anti-PD-1 therapy
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |